Mitsui has exited open source software-focused cybersecurity company Palamida, which had raised $18.5m in funding, in an acquisition by Flexera Software.

Pfizer, Takeda and BB Biotech invested a combined $88m in the offering, conducted less than five months after Myovant spun out of Roivant Sciences.

Novo, Novartis and Amgen all recorded exits as blood disorder therapeutics developer Ra floated in the middle of its range.

Tute Genomics, a bioinformatics software developer backed by Tencent, Intermountain Healthcare and Wilmington Pharmatech, has been bought for an undisclosed sum.

Proofpoint has agreed to purchase cybersecurity software developer FireLayers in a $55m deal, a year after it closed an Akamai-backed funding round.

The purchase of eye-tracking technology developer Eyefluence for an undisclosed amount has provided an exit to backers including Motorola, Intel and Naver.

Stanford University spinout iRhythm, which had raised a total of $115.5m in equity and debt, has gone public in a $107m initial public offering.

The Novo, St. Jude and Kaiser Permanente-backed cardiac diagnostics technology developer floated above its range and closed its first day of trading 53% up on its IPO price.

Bertelsmann and Time Warner have exited Epoxy following the video distribution service's acquisition by Vemba for an undisclosed amount.

Salesforce is set to record a significant exit from cloud services provider Appirio, which had raised about $112m, in a $500m purchase by Wipro.